Innovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk

Dow Jones

Oct 27

0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, HSBC analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. "We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma," the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com)

(END) Dow Jones Newswires

October 27, 2025 03:19 ET (07:19 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578692206"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578692206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578692206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 15:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578692206","market":"sg","top_or_hot":-1,"title":"Innovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 03:19 ET (07:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-27 15:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 03:19 ET (07:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0455707207.USD","symbol_name":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578692206","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578692206","pubTimestamp":1761549540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, HSBC analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","HSHD.SI":"HSBC HK SDR 5to1","BK4207":"综合性银行","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","BK1610":"ETF&股票定投概念","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1601":"香港本地股","BK4585":"ETF&股票定投概念","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","00005":"汇丰控股","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","BK1583":"高瓴概念","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","HSBC":"汇丰","BK1231":"综合性银行","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","01801":"信达生物","BK4521":"英国银行股","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1572":"香港银行股","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1589":"北水核心资产","BK4588":"碎股","HSBA.UK":"汇丰控股有限公司","03143":"华夏香港银行股"},"translate_title":"信达生物通过武田癌症药物合作伙伴关系实现全球增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00005":0.7,"01801":0.9,"03143":0.6,"HSBA.UK":0.6,"HSBC":0.9,"HSHD.SI":0.6},"content_text":"0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, HSBC analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 27, 2025 03:19 ET (07:19 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}